ArticleBMC cancer2025
Constructing a machine learning model for predicting early postoperative recurrence of pancreatic head cancer based on a novel inflammatory factor composite index.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly postoperative recurrence of pancreatic head cancer (PHC) severely affects prognosis. We developed and validated a machine learning (ML)-based model incorporating a novel inflammatory composite index to predict early recurrence in PHC patients.
methodsWe retrospectively analyzed 526 PHC patients who underwent pancreaticoduodenectomy at Fudan University Shanghai Cancer Center (2021–2022). Patients were randomly divided into training (70%) and test (30%) sets. Preoperative clinical, laboratory (ALI, PNI, SIRI), and pathological data were collected. Ten machine learning models were developed and evaluated using AUC, DCA, calibration, and precision-recall curves. The Random Forest model showed the best performance and was interpreted with SHAP.
resultsOf the 526 patients, 164 (31.2%) developed recurrence or metastasis within one year. Multivariate logistic regression identified ALI, CA199, tumor differentiation, capsule integrity, and nerve invasion as independent risk factors. The RF model demonstrated excellent performance, with an AUC of 0.992 in the training set and 0.783 in the test set. SHAP analysis highlighted CA199, ALI, tumor differentiation, capsule status, and nerve invasion as key predictors.
conclusionWe developed and validated an RF-based predictive model incorporating a novel inflammatory index for assessing early recurrence risk in PHC patients, which may aid individualized postoperative management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.